Skip to main content

Advertisement

SpringerLink
Log in

Epilepsy in the cancer patient

  • Mini Review
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Epileptic seizures in patients with malignancies usually occur as a consequence of brain metastases from systemic cancer or the presence of a primary brain tumor. Other less-frequent causes include metabolic disorders such as electrolyte abnormalities, hypoglycemia, hypoxia and liver failure, paraneoplastic encephalitis, leptomeningeal carcinomatosis, side effects of certain chemotherapeutic agents, central nervous system infections, and pre-existing epilepsy.

Methods

We reviewed all published literature in the English language regarding the use of antiepileptic drugs in patients with cancer.

Results

In patients with brain metastases or primary brain tumors that had never experienced seizures, prophylactic anticonvulsant treatment is justified only for a period up to 6 months postoperatively after surgical excision of a cerebral tumor, since approximately half of the patients will never develop seizures and the anti-epileptic drugs may cause toxicity and interactions with antineoplastic therapies. For brief prophylaxis, newer antiepileptic drugs such as levetiracetam and oxcarbazepine are superior to older agents like phenytoin. In patients with a malignancy and seizures, certain antiepileptic drugs that express tumor inhibitory properties should be used such as valproic acid and levetiracetam, followed by oxcarbazepine and topiramate that exhibit good tolerance, efficient seizure control and absence of significant interactions with the chemotherapy.

Conclusions

Future clinical trials in patients with cancer and epilepsy should focus on combinations of chemotherapeutic interventions with antiepileptic drugs that demonstrate antineoplastic activities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Grewal J, Grewal HK, Forman AD (2008) Seizures and epilepsy in cancer: etiologies, evaluation, and management. Curr Oncol Rep 10:63–71

    Article  PubMed  Google Scholar 

  2. Herman ST (2002) Epilepsy after brain insult: targeting epileptogenesis. Neurology 59 (Suppl):S21–S26

    Google Scholar 

  3. van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurols 6:421–430

    Article  Google Scholar 

  4. Bromfield EB (2004) Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis 1(suppl 1):S27–S33

    Google Scholar 

  5. Sioka C, Fotopoulos A, Kyritsis AP (2010) Paraneoplastic neurological syndromes and the role of PET imaging. Oncology 78:150–156

    Article  PubMed  Google Scholar 

  6. Villanueva V, Codina M, Elices E (2008) Management of epilepsy in oncological patients. Neurologist 14(6 (Suppl 1)):S44–S54

    Article  PubMed  Google Scholar 

  7. Sioka C, Kyritsis AP (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761–767

    Article  CAS  PubMed  Google Scholar 

  8. Wen PY, Marks PW (2002) Medical management of patients with brain tumors. Curr Opin Oncol 14:299–307

    Article  PubMed  Google Scholar 

  9. Samji MF, Fric-Shamji EC, Benoit BG (2009) Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev 32:275–285

    Article  Google Scholar 

  10. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724

    CAS  PubMed  Google Scholar 

  11. Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, Raus L, Occhipinti E, Jandolo B (1998) Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res. 17:479–482

    CAS  PubMed  Google Scholar 

  12. Villemure JG, de Tribolet N (1996) Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 9:424–428

    Article  CAS  PubMed  Google Scholar 

  13. Lieu AS, Howng SL (2000) Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 38:45–52

    Article  CAS  PubMed  Google Scholar 

  14. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumours. Reported of the Quality Standard Subcommittee of the American Academy of Neurology. Neurology 54:1886–1893

    CAS  PubMed  Google Scholar 

  15. Liigant A, Haldre S, Oun A, Linnamagi U, Saar A, Asser T, Kaasik AE (2001) Seizure disorders in patients with brain tumors. Eur Neurol 45:46–51

    Article  CAS  PubMed  Google Scholar 

  16. Rajneesh KF, Binder DK (2009) Tumor-associated epilepsy. Neurosurg Focus 27:E4

    Article  PubMed  Google Scholar 

  17. Beaumont A, Whittle IR (2000) The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien) 142:1–15

    Article  CAS  Google Scholar 

  18. Kurzwelly D, Herrlinger U, Simon M (2010) Seizures in patients with low-grade gliomas–incidence, pathogenesis, surgical management, and pharmacotherapy. Adv Tech Stand Neurosurg 35:81–111

    Article  CAS  PubMed  Google Scholar 

  19. Schaller B (2005) Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis. Acta Neurol Scand 111:75–83

    Article  CAS  PubMed  Google Scholar 

  20. Kim E, Lowenson JD, MacLaren DC, Clarke S, Young SG (1997) Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. Proc Natl Acad Sci USA 94:6132–6137

    Article  CAS  PubMed  Google Scholar 

  21. Aronica E, Gorter JA, Jansen GH, Leenstra S, Yankaya B, Troost D (2001) Expression of connexin 43 and connexin 32 gapjunction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol 101:449–459

    CAS  PubMed  Google Scholar 

  22. Bateman DE, Hardy JA, McDermott JR, Parker DS, Edwardson JA (1988) Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res 10:112–114

    CAS  PubMed  Google Scholar 

  23. Maas S, Patt S, Schrey M, Rich A (2001) Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA 98:14687–14692

    Article  CAS  PubMed  Google Scholar 

  24. Mody I, Heinemann U (1987) NMDA receptors of dentate gyrus granule cells participate in synaptic transmission following kindling. Nature 326:701–704

    Article  CAS  PubMed  Google Scholar 

  25. Siomin V, Angelov L, Li L, Vogelbaum MA (2005) Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neurooncol 74:211–215

    Article  CAS  PubMed  Google Scholar 

  26. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS (2004) Seizure prophylaxis in patients with brain tumors: a metanalysis. Mayo Clin Proc 79:1489–1494

    Article  PubMed  Google Scholar 

  27. Rosati A, Tomassini A, Pollo B, Ambrosi C, Schwarz A, Padovani A, Bonetti B (2009) Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol 93:395–400

    Article  PubMed  Google Scholar 

  28. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR (2008) Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 16:CD004424. Review

  29. Forsyth PA, Weaver S, Fulton D, Brasher PM, Sutherland G, Stewart D, Hagen NA, Barnes P, Cairncross JG, DeAngelis LM (2003) Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30:106–112

    PubMed  Google Scholar 

  30. Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:97–102

    Article  PubMed  Google Scholar 

  31. Shaw MD (1990) Post-operative epilepsy and the efficacy of anticonvulsant therapy. Acta Neurochir Suppl (Wien) 50:55–57

    CAS  Google Scholar 

  32. Franceschetti S, Binelli S, Casazza M, Lodrini S, Panzica F, Pluchino F, Solero CL, Avanzini G (1990) Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien) 103:47–51

    Article  CAS  Google Scholar 

  33. Mauro AM, Bomprezzi C, Morresi S, Provinciali L, Formica F, Iacoangeli M, Scerrati M (2007) Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neurooncol 81:279–285

    Article  CAS  PubMed  Google Scholar 

  34. Zachenhofer I, Donat M, Oberndorfer S, Roessler K (2010) Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neurooncol [Epub ahead of print]

  35. De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E (2002) Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 43:175–182

    Article  PubMed  Google Scholar 

  36. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101:9861–9866

    Article  CAS  PubMed  Google Scholar 

  37. Dinapoli L, Maschio M, Jandolo B, Fabi A, Pace A, Sperati F, Muti P (2009) Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci 30:353–359

    Article  Google Scholar 

  38. Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, Chang S, Lamborn KR, McDermott MW (2009) Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II study. J Neurooncol 93:349–354

    Article  CAS  PubMed  Google Scholar 

  39. Usery JB, Michael LM 2nd, Sills AK, Finch CK (2010) A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol. [Epub ahead of print]

  40. Newton HB, Dalton J, Goldlust S, Pearl D (2007) Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 84:293–296

    Article  CAS  PubMed  Google Scholar 

  41. Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:99–102

    Article  CAS  PubMed  Google Scholar 

  42. Maschio M, Albani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, Pompili A, Carapella CM, Occhipinti E, Jandolo B (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80:97–100

    Article  CAS  PubMed  Google Scholar 

  43. Lee JW, Bromfield EB, Kesari S (2008) Antiemetic properties of the antiepileptic drug levetiracetam. N Engl J Med 359:1853

    Article  CAS  PubMed  Google Scholar 

  44. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256:1519–1526

    Article  PubMed  Google Scholar 

  45. Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, Giannarelli D, Occhipinti E, Jandolo B (2008) Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 86:61–70

    Article  CAS  PubMed  Google Scholar 

  46. Maschio M, Dinapoli L, Vidiri A, Pace A, Fabi A, Pompili A, Carapella MC, Jandolo B (2009) The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 28:60

    Article  PubMed  Google Scholar 

  47. Vecht CJ, Wilms EB (2010) Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 10:663–669

    Article  PubMed  Google Scholar 

  48. Perry JR, Sawka C (1996) Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 23:128–131

    CAS  PubMed  Google Scholar 

  49. Striano S, Striano P, Boccella P, Nocerino C, Bilo L (2002) Tiagabine in glial tumors. Epilepsy Res 49:81–85

    Article  CAS  PubMed  Google Scholar 

  50. Novy J, Stupp R, Rossetti AO (2009) Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 111:171–173

    Article  PubMed  Google Scholar 

  51. Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, Muti P, Jandolo B (2010) Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol 98:109–116

    Article  CAS  PubMed  Google Scholar 

  52. Cohen N, Strauss G, Lew R, Silver D, Recht L (1988) Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 6:1621–1624

    CAS  PubMed  Google Scholar 

  53. Drane DL, Meador KJ (2002) Cognitive and behavioral effects of antiepileptic drugs. Epilepsy Behav 3:49–53

    Article  PubMed  Google Scholar 

  54. Delattre J, Safai B, Posner JB (1988) Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 38:194–198

    CAS  PubMed  Google Scholar 

  55. Khe HX, Delattre JY, Poisson M (1990) Stevens-Johnson syndrome in a patient receiving cranial irradiation and carbamazepine. Neurology 40:1144–1145

    Google Scholar 

  56. Mamon HJ, Wen PY, Burns AC, Loeffler JS (1999) Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 40:341–344

    Article  CAS  PubMed  Google Scholar 

  57. Aguiar D, Pazo R, Duran I, Terrasa J, Arrivi A, Manzano H, Martin J, Rifa J (2004) Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 66:345–350

    Article  PubMed  Google Scholar 

  58. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361–1368

    Article  CAS  PubMed  Google Scholar 

  59. Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246–255

    Article  CAS  PubMed  Google Scholar 

  60. Yap KY, Chui WK, Chan A (2008) Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 30:1385–1407

    Article  CAS  PubMed  Google Scholar 

  61. Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404–409

    Article  CAS  PubMed  Google Scholar 

  62. Ruggiero A, Rizzo D, Mastrangelo S, Battaglia D, Attinà G, Riccardi R (2010) Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? Pediatr Blood Cancer 54:193–198

    PubMed  Google Scholar 

  63. Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser M, Dresemann G (2008) Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 3:198–203

    Article  CAS  PubMed  Google Scholar 

  64. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium (2010) A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12:87–94

    CAS  PubMed  Google Scholar 

  65. Avila EK, Graber J (2010) Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep 10:60–67

    Article  PubMed  Google Scholar 

  66. Sisodiya SM (2003) Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 16:197–201

    Article  CAS  PubMed  Google Scholar 

  67. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121

    Article  CAS  PubMed  Google Scholar 

  68. Gottlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978

    Article  CAS  PubMed  Google Scholar 

  69. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734–36741

    Article  CAS  PubMed  Google Scholar 

  70. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206–222

    Article  CAS  PubMed  Google Scholar 

  71. Benítez JA, Arregui L, Cabrera G, Segovia J (2008) Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. Neuroscience 156:911–920

    Article  PubMed  Google Scholar 

  72. Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J (2002) Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE (2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 20:97–106

    CAS  PubMed  Google Scholar 

  73. Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM, Fulda S (2009) Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 28:3097–3110

    Article  PubMed  Google Scholar 

  74. Knüpfer MM, Pulzer F, Schindler I, Hernaíz Driever P, Knüpfer H, Keller E (2001) Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 21:347–351

    PubMed  Google Scholar 

  75. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, Gopalakrishnan V (2007) Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85:159–170

    Article  CAS  PubMed  Google Scholar 

  76. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912–1922

    Article  CAS  PubMed  Google Scholar 

  77. Venkataramani V, Rossner C, Iffland L, Schweyer S, Tamboli IY, Walter J, Wirths O, Bayer TA (2010) Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem 285:10678–10689

    Article  CAS  PubMed  Google Scholar 

  78. Papi A, Ferreri AM, Rocchi P, Guerra F, Orlandi M (2010) Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res 30:535–540

    CAS  PubMed  Google Scholar 

  79. Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, Blaney SM, Lau CC, Li XN (2006) Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res 12:4687–4694

    Article  CAS  PubMed  Google Scholar 

  80. Ciusani E, Balzarotti M, Calatozzolo C, de Grazia U, Boiardi A, Salmaggi A, Croci D (2007) Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 16:453–463

    Article  CAS  PubMed  Google Scholar 

  81. Jawed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES, Niles LP (2007) Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 560:17–22

    Article  CAS  PubMed  Google Scholar 

  82. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP (2010) Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 12:328–340

    CAS  PubMed  Google Scholar 

  83. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380–386

    Article  CAS  PubMed  Google Scholar 

  84. Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410–5415

    Article  CAS  PubMed  Google Scholar 

  85. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, Konduri SD (2010) Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12:917–927

    Article  CAS  PubMed  Google Scholar 

  86. Silber JR, Mueller BA, Ewers TG, Berger MS (1993) Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res 53:3416–3420

    CAS  PubMed  Google Scholar 

  87. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  CAS  PubMed  Google Scholar 

  88. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255–260

    Article  CAS  PubMed  Google Scholar 

  89. Jaeckle KA, Ballman K, Furth A, Buckner JC (2009) Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207–1213

    Article  CAS  PubMed  Google Scholar 

  90. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG, Evans WE (2000) Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356:285–290

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurosurgical Research Institute, University of Ioannina, Ioannina, Greece

    Odysseas Kargiotis & Athanasios P. Kyritsis

  2. Department of Neurology, University Hospital of Patras Medical School, University Campus, 26504, Patras, Greece

    Odysseas Kargiotis

  3. Department of Neurology, University Hospital of Ioannina Medical School, Ioannina, Greece

    Sofia Markoula & Athanasios P. Kyritsis

Authors
  1. Odysseas Kargiotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sofia Markoula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Athanasios P. Kyritsis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Odysseas Kargiotis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kargiotis, O., Markoula, S. & Kyritsis, A.P. Epilepsy in the cancer patient. Cancer Chemother Pharmacol 67, 489–501 (2011). https://doi.org/10.1007/s00280-011-1569-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1569-0

Keywords

Search

Navigation